A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Todd M BauerKathleen M MooreJanet S RaderFiona SimpkinsAlain C MitaJ Thaddeus BeckLowell HartQuincy ChuAmit OzaSarah A CookEsteban Rodrigo ImedioSanjeev KumarGanesh MugunduSuzanne JenkinsJuliann ChmieleckiSuzanne F JonesDavid R SpigelSiqing FuPublished in: Targeted oncology (2023)
ClinicalTrials.gov identifier NCT02482311; registered June 2015.